Physician profile
Mitchell Runge
NPI 1497231013
$2,310.89
in general payments reported to CMS, 2019-2025
28 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.67 · 2024: $525 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,284.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $290.61 | 2024-2025 | |
| Novo Nordisk INC | $270.91 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $224.18 | 2024-2025 | Kisunla, Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $177.90 | 2025 | Auvelity, Symbravo |
| Amgen INC. | $169.23 | 2024-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $161.13 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $157.70 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $152.49 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $94.79 | 2024-2025 | |
| Eisai INC. | $59.28 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $58.62 | 2024-2025 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.02 | 2024-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $41.14 | 2022-2024 | Capvaxive, Gardasil 9, Gardasil |
| Aimmune Therapeutics, INC. | $39.60 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $37.63 | 2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $36.45 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $35.75 | 2025 | Zoryve |
| Lundbeck LLC | $33.77 | 2025 | Vyepti |
| Exact Sciences Corporation | $32.58 | 2025 | Cologuard Collection Kit |
| Globus Medical, INC. | $30.66 | 2025 | Senza |
| Sanofi-Aventis U.S. LLC | $25.53 | 2024 | |
| Edwards Lifesciences Corporation | $23.53 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $22.22 | 2024 | |
| Medtronic, INC. | $21.38 | 2025 | Inceptiv |
| Abbott Laboratories | $19.09 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $17.46 | 2024 | Gemtesa |
| Dynavax Technologies Corporation | $15.36 | 2025 | Heplisav-B |
| Otsuka America Pharmaceutical, INC. | $14.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Runge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.